- Home
- HALO
as 11-22-2024 4:00pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 6.4B | IPO Year: | N/A |
| Target Price: | $61.11 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.02 | EPS Growth: | 61.71 |
| 52 Week Low/High: | $33.15 - $65.53 | Next Earning Date: | 10-31-2024 |
| Revenue: | $947,355,000 | Revenue Growth: | 21.35% |
| Revenue Growth (this year): | 23.36% | Revenue Growth (next year): | 15.15% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Oct 15 '24 | Sell | $53.75 | 20,000 | $1,070,058.65 | 173,756 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Oct 8 '24 | Sell | $53.52 | 20,000 | $1,065,743.18 | 676,744 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Sep 24 '24 | Sell | $56.88 | 30,000 | $1,706,440.00 | 676,744 | |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Sep 17 '24 | Sell | $62.45 | 20,000 | $1,249,095.53 | 173,756 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Sep 10 '24 | Sell | $59.13 | 30,000 | $1,773,790.00 | 676,744 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Sector Update: Health Care Stocks Rise Friday Afternoon
Benzinga
a day ago
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
Zacks
a day ago
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
Zacks
a day ago
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Investing.com
a day ago
Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal
MT Newswires
a day ago
Sector Update: Health Care Stocks Advance Premarket Friday
MT Newswires
a day ago
Update: Halozyme Therapeutics Withdraws Proposal to Acquire Evotec
MT Newswires
a day ago
Sector Update: Health Care
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.